What contract did IMEXHS (ASX:IME) secure in Mexico?

IMEXHS has won a major public tender contract to deploy its Aquila+ medical imaging platform across 20 public hospitals and clinics in Zacatecas, Mexico.

How much revenue will the Mexican contract generate for IMEXHS (ASX:IME)?

The contract adds approximately $384,000 in new Annual Recurring Revenue (ARR) to the company's financial profile. Additionally, IMEXHS will receive a one-off implementation fee of $50,000 to cover the network-wide deployment costs.

What is the timeline for the IMEXHS (ASX:IME) rollout in Mexico?

The software upgrade is scheduled for completion across all 20 clinical sites by the end of June. Following an initial transition period, IMEXHS expects the contract to reach its full ARR run rate from September.

What makes this IMEXHS (ASX:IME) deployment technically significant?

The deployment is positioned as one of the most comprehensive AI-integrated radiology projects globally. It embeds five of IMEXHS’s proprietary AI workflow agents into Aquila+, combined with two clinical diagnostic AI tools from partner Gleamer called ChestView and Fracture Detection.

How does the Mexican tender win fit into the long-term strategy for IMEXHS (ASX:IME)?

This contract advances the company's international expansion strategy by deepening its footprint in the Latin American healthcare market. It also demonstrates management's capacity to successfully compete for and win high-volume, public sector procurement contracts.

Tech

Image for illustrative purposes only. Not a real photo.

IMEXHS deploys AI radiology tech across Mexico

Written by Heidi Cuthbert Published May. 25 2026Last Updated May. 25 2026

Australian-listed medical technology company IMEXHS (ASX:IME) has secured a major public tender contract to deploy its advanced Aquila+ imaging platform across 20 hospitals and clinics in Zacatecas, Mexico.

The deal, achieved in partnership with local distributor GOBA, marks a significant milestone in the company’s international expansion strategy and highlights its growing competitiveness in public sector procurement.

The contract is set to deliver an immediate financial boost to IMEXHS, contributing approximately $384,000 in new annual recurring revenue, alongside a one-off implementation fee of $50,000.

The deployment stands out as one of the most comprehensive AI-integrated radiology projects undertaken globally.

It will integrate five of IMEXHS’s proprietary AI workflow agents directly into the Aquila+ platform.

The software will feature two specialised AI diagnostic tools from partner Gleamer: ChestView and Fracture Detection.

The combination of automated workflow management and diagnostic AI aims to streamline operations and enhance clinical accuracy across the region's public healthcare network.

Implementation of the network-wide software upgrade has already commenced. The rollout is scheduled for completion across all 20 clinical sites by the end of June.

Following the initial transition period, the company expects the contract to reach its full ARR run rate from September.

At the time of reporting, IMEXHS’ share price was $0.38.